Based on the analysis of 2Seventy Bio's profitability, liquidity, and operating efficiency, 2Seventy Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, 2Seventy Bio's Net Receivables is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 574.1 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 12.4 M in 2024. Key indicators impacting 2Seventy Bio's financial strength include:
The essential information of the day-to-day investment outlook for 2Seventy Bio includes many different criteria found on its balance sheet. An individual investor should monitor 2Seventy Bio's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in 2Seventy Bio.
Net Income
(228.45 Million)
2Seventy
Select Account or Indicator
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Common Stock Shares Outstanding
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Retained Earnings
Short Term Investments
Long Term Investments
Capital Stock
Net Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Interest Income
Probability Of Bankruptcy
Understanding current and past 2Seventy Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of 2Seventy Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in 2Seventy Bio's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in 2Seventy Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of 2Seventy Bio. Check 2Seventy Bio's Beneish M Score to see the likelihood of 2Seventy Bio's management manipulating its earnings.
2Seventy Bio Stock Summary
2Seventy Bio competes with Puma Biotechnology, Iovance Biotherapeutics, Sarepta Therapeutics, Day One, and Inozyme Pharma. 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2Seventy Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining 2Seventy Bio's current stock value. Our valuation model uses many indicators to compare 2Seventy Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across 2Seventy Bio competition to find correlations between indicators driving 2Seventy Bio's intrinsic value. More Info.
2Seventy Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, 2Seventy Bio's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value 2Seventy Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
2Seventy Bio Systematic Risk
2Seventy Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. 2Seventy Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on 2Seventy Bio correlated with the market. If Beta is less than 0 2Seventy Bio generally moves in the opposite direction as compared to the market. If 2Seventy Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one 2Seventy Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of 2Seventy Bio is generally in the same direction as the market. If Beta > 1 2Seventy Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in 2Seventy Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various 2Seventy Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of 2Seventy Bio growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of 2Seventy Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of 2Seventy Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of 2Seventy Bio based on widely used predictive technical indicators. In general, we focus on analyzing 2Seventy Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build 2Seventy Bio's daily price indicators and compare them against related drivers.
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.